This website is no longer active. Please click the following link to get to our new site:
stillwater.support.myeloma.org
Please bookmark this new site or the appropriate local support group page. Thank you and sorry for any inconvenience.
PubMed Myeloma News- Diagnostic value of LGE and T1 mapping in multiple myeloma patients'heart
- Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
- Psychological distress and mental health care utilization among Black survivors of adolescent and young adult cancer
- Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma
- Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
- Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma
- The eEF1A Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies
- Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?
- Batimastat Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Hematological Tumors
- Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
- MedWorm Myeloma Headlines
- An error has occurred; the feed is probably down. Try again later.
- Medical Xpress Myeloma
- Biomarkers identified for successful treatment of bone marrow tumors
- Targeting specific protein regions offers a new treatment approach in medulloblastoma
- Stem cell transplants and survival rates on the rise across all racial and ethnic groups
- Study reviews the role of a ribonucleic acid 'MALAT1' in hematological malignancies
- Study points to racial and social barriers that block treatment for multiple myeloma
- AI tool predicts responses to cancer therapy using information from each cell of the tumor
- FDA approves Abecma for relapsed, refractory multiple myeloma
- Model predicts need for bone marrow sampling in monoclonal gammopathy of undetermined significance
- New research identifies promising drug combination for multiple myeloma treatment
- Lymph node-like biomaterial scaffold for augmenting CAR-T cell therapy
myelomasmn.wordpress.com 